Navigation Links
Former VP of Clinical Pharmacology at Nektar Therapeutics, Michael A. Eldon, PhD, FCP, Joins NDA Partners as Expert Consultant

NDA Partners Chairman Carl Peck, MD, announced today that Dr. Michael A. Eldon, the former Vice President of Clinical Pharmacology at Nektar Therapeutics, and a clinical pharmacology, pharmacokinetics/pharmacodynamics and pharmacometrics expert with more than thirty-five years of experience in the pharmaceutical industry, has joined the firm as an Expert Consultant.

As Vice President of Clinical Pharmacology at Nektar Therapeutics, Dr. Eldon was responsible for clinical and preclinical pharmacokinetics, ADME, pharmacometrics and systems biology in drug development and discovery.

Prior to Nektar, Dr. Eldon worked at Parke-Davis Pharmaceutical Research where he participated in the development and registration of Lipitor (atorvastatin), Neurontin (gabapentin), Rezulin (troglitazone), Lyrica (pregabalin), Pro-Air (procaterol), Lopid (gemfibrozil), Loestrin (oral contraceptive), Estrostep (oral contraceptive), Procanbid (procainamide extended release), FemPatch (transdermal estradiol), Cerebyx (fosphenytoin), Penetrex (enoxacin), Zagam (sparfloxacin) and Nitrostat (nitroglycerin) stabilized tablets. While at Nektar, he participated in the discovery, development, and registration of Movantik and Exubera (rH insulin for inhalation); and the discovery and preclinical and clinical development of other Nektar proprietary products including Onzeald (etirinotecan pegol), NKTR-181, and NKTR-214.

“Dr. Eldon’s extensive experience in clinical pharmacology, PK/PD, and pharmacometrics make him an excellent resource for our clients in the preclinical and clinical drug development phases,” said Dr. Carl Peck. “We are very pleased he has joined NDA Partners.”

Dr. Eldon earned his doctorate degree in Biopharmaceutics and Pharmacokinetics and a Bachelors of Science degree in Pharmacy from the University of Cincinnati. He is a member of several pharmaceutical societies, is a Fellow of the American College of Clinical Pharmacology, and has authored over 150 scientific articles and presentations.

About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.

Earle Martin, Chief Executive Officer
Office: 540-738-2550

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Former Associate Director of Product Development R&D at Allergan, Melissa Kirkegaard, joins NDA Partners as Expert Consultant
2. Former Vice President of Development Operations at XenoPort, Sami Karaborni, PhD, joins NDA Partners as Expert Consultant
3. Former CEO of Eurofins Advantar Laboratories, Richard Kenley, PhD, joins NDA Partners as Expert Consultant
4. Former FDA Official to Conduct Popular ComplianceOnline Seminar on FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials
5. Former P&G VP Appointed New Industry Expert at Verixs Advisory Board
6. Former Director of FDA Division of Biostatistics, Gregory Campbell, PhD, joins NDA Partners as Expert Consultant
7. Vinod Shah, PhD, Former Senior Research Scientist in FDA Office of Pharmaceutical Sciences, Joins NDA Partners as Expert Consultant
8. Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
9. Dr. Daniel Spyker, Former FDA acting Deputy Division Director of Cardiovascular, Respiratory, and Neurological Devices, Joins NDA Partners
10. Repetitive Head Injuries May Not Cause Movement Problems for Former NFL Players
11. Dr. Deborah Wenkert Pediatrics Expert and Former Amgen Clinical Research Medical Director, Joins NDA Partners
Post Your Comments:
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is ... and 8th June 2018 in San Francisco, CA. The Summit brings together current and ... distinguished CEOs, board directors and government officials from around the world to address key ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
Breaking Biology News(10 mins):